123 related articles for article (PubMed ID: 19841470)
1. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
Spallarossa P; Altieri P; Pronzato P; Aloi C; Ghigliotti G; Barsotti A; Brunelli C
J Pharmacol Exp Ther; 2010 Jan; 332(1):87-96. PubMed ID: 19841470
[TBL] [Abstract][Full Text] [Related]
2. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
[TBL] [Abstract][Full Text] [Related]
3. Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells.
Attia SM; Ahmad SF; Saquib Q; Harisa GI; Al-Khedhairy AA; Bakheet SA
Mutagenesis; 2016 Mar; 31(2):137-45. PubMed ID: 26399706
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating PI3K/Akt pathway in cardiomyocytes.
Chen S; Liu J; Liu X; Fu Y; Zhang M; Lin Q; Zhu J; Mai L; Shan Z; Yu X; Yang M; Lin S
J Ethnopharmacol; 2011 Sep; 137(1):263-70. PubMed ID: 21619920
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes.
Pentassuglia L; Timolati F; Seifriz F; Abudukadier K; Suter TM; Zuppinger C
Exp Cell Res; 2007 May; 313(8):1588-601. PubMed ID: 17400210
[TBL] [Abstract][Full Text] [Related]
8. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
9. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
10. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
Grazette LP; Boecker W; Matsui T; Semigran M; Force TL; Hajjar RJ; Rosenzweig A
J Am Coll Cardiol; 2004 Dec; 44(11):2231-8. PubMed ID: 15582322
[TBL] [Abstract][Full Text] [Related]
12. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death.
Singh KK; Shukla PC; Quan A; Lovren F; Pan Y; Wolfstadt JI; Gupta M; Al-Omran M; Leong-Poi H; Teoh H; Verma S
Biochem Biophys Res Commun; 2011 Jul; 411(2):421-6. PubMed ID: 21749857
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide pretreatment protects cardiomyocytes against hypoxia-induced cell death by improving mitochondrial stress.
Tong DL; Zhang DX; Xiang F; Teng M; Jiang XP; Hou JM; Zhang Q; Huang YS
Pharmacology; 2012; 90(1-2):11-8. PubMed ID: 22699421
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective effect of zinc requires ErbB2 and Akt during hypoxia/reoxygenation.
Viswanath K; Bodiga S; Balogun V; Zhang A; Bodiga VL
Biometals; 2011 Feb; 24(1):171-80. PubMed ID: 20809125
[TBL] [Abstract][Full Text] [Related]
15. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways.
Pugatsch T; Abedat S; Lotan C; Beeri R
Breast Cancer Res; 2006; 8(4):R35. PubMed ID: 16839426
[TBL] [Abstract][Full Text] [Related]
16. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
Hasinoff BB
Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effect of breviscapine: inhibition of apoptosis in H9c2 cardiomyocytes via the PI3K/Akt/eNOS pathway following simulated ischemia/reperfusion injury.
Wang J; Ji SY; Liu SZ; Jing R; Lou WJ
Pharmazie; 2015 Sep; 70(9):593-7. PubMed ID: 26492644
[TBL] [Abstract][Full Text] [Related]
19. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Plandé J; Platel D; Tariosse L; Robert J
Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
[TBL] [Abstract][Full Text] [Related]
20. Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.
Zhang S; Meng T; Liu J; Zhang X; Zhang J
Medicine (Baltimore); 2015 Jan; 94(4):e445. PubMed ID: 25634181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
